(RTTNews) - Thursday, Roche (RHHBY) reported new data from the VOYAGER study showing that Vabysmo (faricimab) delivered durable effectiveness and a consistent safety profile in patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edem
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.